Renovis files $100 million shelf

By Ted A. Knutson

Washington, Feb.11 - Renovis, Inc. filed a $100 million shelf registration with the Securities and Exchange Commission.

Securities authorized to be sold under the shelf are debt securities, common stock, preferred stock and warrants. The shelf also allows for the sale of convertibles.

The San Francisco-based biopharmaceutical company said proceeds from offerings authorized by the shelf would be used for general corporate purposes, including clinical trials, research and development expenses, general and administrative expenses, manufacturing expenses and potential acquisitions of companies, products and technologies that complement its business.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.